Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHYF) Current Deferred Revenue (2017 - 2025)

Historic Current Deferred Revenue for Innate Pharma (IPHYF) over the last 9 years, with Q2 2025 value amounting to $637293.3.

  • Innate Pharma's Current Deferred Revenue fell 7885.7% to $637293.3 in Q2 2025 from the same period last year, while for Jun 2025 it was $637293.3, marking a year-over-year decrease of 7885.7%. This contributed to the annual value of $658254.7 for FY2024, which is 8956.87% down from last year.
  • Per Innate Pharma's latest filing, its Current Deferred Revenue stood at $637293.3 for Q2 2025, which was down 7885.7% from $658254.7 recorded in Q4 2024.
  • Over the past 5 years, Innate Pharma's Current Deferred Revenue peaked at $14.3 million during Q4 2021, and registered a low of $637293.3 during Q2 2025.
  • Moreover, its 5-year median value for Current Deferred Revenue was $6.3 million (2023), whereas its average is $6.6 million.
  • Examining YoY changes over the last 5 years, Innate Pharma's Current Deferred Revenue showed a top increase of 614.59% in 2021 and a maximum decrease of 9996.97% in 2021.
  • Innate Pharma's Current Deferred Revenue (Quarter) stood at $14.3 million in 2021, then plummeted by 53.2% to $6.7 million in 2022, then fell by 5.71% to $6.3 million in 2023, then tumbled by 89.57% to $658254.7 in 2024, then fell by 3.18% to $637293.3 in 2025.
  • Its last three reported values are $637293.3 in Q2 2025, $658254.7 for Q4 2024, and $3.0 million during Q2 2024.